Last reviewed 2026-04-19 · How we verify

Multiple

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Phase I, Open Label, Dose Escalation Study to Investigate the Tolerability and Efficacy of APO010 in Patients With Relapsed/Refractory Multiple Myeloma Selected by Drug Response Predictor (DRP) (Phase 1)
• The Effect of Quick Response (QR) Coded Teaching Plan, Prepared According to Health Literacy Levels of Patients With Total Knee Replacement Surgery, on Recovery Process and Quality of Life (NA)
• Self-Monitoring of Transcutaneous Bilirubinometry in Healthy Term and Near-Term Neonates: a Multi-center Prospective Study (N/A)
• A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (Phase 2)
• Multi-Omic Microbiome Study: Characterization of the Human Microbiota Among Chinese Population to Understant How the Microbiome Impacts Human Health. (N/A)
• Ex Vivo Multi Drug Screening of Solid Tumours to Determine Personalised Therapy Efficacy and Resistance (N/A)
• Fall Risk Reduction in Multiple Sclerosis: Exercise Intervention vs. Attention Control Modification (NA)
• The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine. A Multi-Center, Randomized, Double-Blind, Clinical Control Trial (Phase 3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Multiple CI brief — competitive landscape report
• Multiple updates RSS · CI watch RSS
• University of Oxford portfolio CI